This Portrazza market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historic period can be attributed to factors such as growing tobacco consumption, the availability of reimbursement schemes, the increasing prevalence of lung cancer, rising incidence rates of the disease, and increased investment in cancer research.
The growth anticipated in the forecast period can be attributed to factors such as a focus on quality-of-life improvements, an increasing number of specialized cancer centers, rising cancer awareness in emerging economies, a growing number of clinical trials, and the increasing adoption of targeted therapies. Key trends during this period include the integration of robotics in cancer treatment, technological advancements in drug formulation, progress in tumor profiling, the use of artificial intelligence in drug development, and the application of next-generation sequencing (NGS) in cancer treatment.
The rising incidence of lung cancer is expected to drive the growth of the Portrazza market. Lung cancer, a type of cancer that begins in the lungs and may spread to other parts of the body, is becoming more common due to factors such as smoking, exposure to environmental pollutants, genetic predisposition, and occupational hazards such as asbestos. Portrazza (necitumumab) helps treat lung cancer by targeting the epidermal growth factor receptor (EGFR), which is crucial in the growth and spread of cancer cells. This slows the progression of non-small cell lung cancer (NSCLC) when combined with chemotherapy. For example, the American Cancer Society reported that the estimated number of new lung and bronchus cancer cases in the US increased from 236,740 in 2022 to 238,340 in 2023. As a result, the rising incidence of lung cancer is driving the growth of the Portrazza market.
Rising healthcare expenditure is expected to fuel the growth of the Portrazza market. Healthcare expenditure refers to the total spending on medical services, including hospital care, physician services, prescription drugs, and other healthcare products. The growth in healthcare spending is attributed to factors such as an aging population, the rise of chronic diseases, advancements in medical technologies, and increased healthcare demand. This increased expenditure on healthcare supports the accessibility of Portrazza for patients with advanced squamous non-small cell lung cancer (NSCLC) and funds research, treatment protocols, and targeted therapies. In December 2023, the Centers for Medicare & Medicaid Services reported that US healthcare spending rose by 4.1% in 2022, totaling $4.5 trillion, exceeding the previous year's growth rate of 3.2%. Therefore, the rising healthcare expenditure is driving the growth of the Portrazza market.
The shift toward personalized medicine is expected to further boost the growth of the Portrazza market. Personalized medicine tailors healthcare treatments to individual patients based on their genetic makeup and other personal factors. Advances in genomics, biotechnology, and data analytics have facilitated this shift by enabling more precise treatments. Portrazza (necitumumab) supports personalized medicine by targeting the epidermal growth factor receptor (EGFR), specifically treating non-small cell lung cancer (NSCLC) with EGFR expression. This approach offers a more individualized treatment based on a patient’s unique biomarker profile. In February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from the six approvals in 2022. As a result, the shift toward personalized medicine is contributing to the growth of the Portrazza market.
The key company operating in the portrazza market is Eli Lilly and Company.
North America was the largest region in the portrazza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in portrazza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the portrazza market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Portrazza is a biologic drug containing necitumumab, a monoclonal antibody used in the treatment of non-small cell lung cancer (NSCLC). It works by targeting and blocking the epidermal growth factor receptor (EGFR), which plays a role in the growth and survival of cancer cells.
The main indications for Portrazza include metastatic squamous non-small cell lung cancer (NSCLC) and locally advanced squamous NSCLC. Metastatic squamous NSCLC refers to a stage where the cancer has spread to other parts of the body, and treatments focus on controlling its progression and improving the patient's quality of life. The drug is distributed through various channels, such as direct sales, pharmaceutical wholesalers, and online pharmacies. Its end users include hospitals, oncology clinics, and home healthcare providers.
The portrazza market research report is one of a series of new reports that provides portrazza market statistics, including the portrazza industry global market size, regional shares, competitors with the portrazza market share, detailed portrazza market segments, market trends, and opportunities, and any further data you may need to thrive in the portrazza industry. This portrazza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The portrazza market consists of sales of portrazza (necitumumab) injections, chemotherapy drugs, and supportive care drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historic period can be attributed to factors such as growing tobacco consumption, the availability of reimbursement schemes, the increasing prevalence of lung cancer, rising incidence rates of the disease, and increased investment in cancer research.
The growth anticipated in the forecast period can be attributed to factors such as a focus on quality-of-life improvements, an increasing number of specialized cancer centers, rising cancer awareness in emerging economies, a growing number of clinical trials, and the increasing adoption of targeted therapies. Key trends during this period include the integration of robotics in cancer treatment, technological advancements in drug formulation, progress in tumor profiling, the use of artificial intelligence in drug development, and the application of next-generation sequencing (NGS) in cancer treatment.
The rising incidence of lung cancer is expected to drive the growth of the Portrazza market. Lung cancer, a type of cancer that begins in the lungs and may spread to other parts of the body, is becoming more common due to factors such as smoking, exposure to environmental pollutants, genetic predisposition, and occupational hazards such as asbestos. Portrazza (necitumumab) helps treat lung cancer by targeting the epidermal growth factor receptor (EGFR), which is crucial in the growth and spread of cancer cells. This slows the progression of non-small cell lung cancer (NSCLC) when combined with chemotherapy. For example, the American Cancer Society reported that the estimated number of new lung and bronchus cancer cases in the US increased from 236,740 in 2022 to 238,340 in 2023. As a result, the rising incidence of lung cancer is driving the growth of the Portrazza market.
Rising healthcare expenditure is expected to fuel the growth of the Portrazza market. Healthcare expenditure refers to the total spending on medical services, including hospital care, physician services, prescription drugs, and other healthcare products. The growth in healthcare spending is attributed to factors such as an aging population, the rise of chronic diseases, advancements in medical technologies, and increased healthcare demand. This increased expenditure on healthcare supports the accessibility of Portrazza for patients with advanced squamous non-small cell lung cancer (NSCLC) and funds research, treatment protocols, and targeted therapies. In December 2023, the Centers for Medicare & Medicaid Services reported that US healthcare spending rose by 4.1% in 2022, totaling $4.5 trillion, exceeding the previous year's growth rate of 3.2%. Therefore, the rising healthcare expenditure is driving the growth of the Portrazza market.
The shift toward personalized medicine is expected to further boost the growth of the Portrazza market. Personalized medicine tailors healthcare treatments to individual patients based on their genetic makeup and other personal factors. Advances in genomics, biotechnology, and data analytics have facilitated this shift by enabling more precise treatments. Portrazza (necitumumab) supports personalized medicine by targeting the epidermal growth factor receptor (EGFR), specifically treating non-small cell lung cancer (NSCLC) with EGFR expression. This approach offers a more individualized treatment based on a patient’s unique biomarker profile. In February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from the six approvals in 2022. As a result, the shift toward personalized medicine is contributing to the growth of the Portrazza market.
The key company operating in the portrazza market is Eli Lilly and Company.
North America was the largest region in the portrazza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in portrazza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the portrazza market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Portrazza is a biologic drug containing necitumumab, a monoclonal antibody used in the treatment of non-small cell lung cancer (NSCLC). It works by targeting and blocking the epidermal growth factor receptor (EGFR), which plays a role in the growth and survival of cancer cells.
The main indications for Portrazza include metastatic squamous non-small cell lung cancer (NSCLC) and locally advanced squamous NSCLC. Metastatic squamous NSCLC refers to a stage where the cancer has spread to other parts of the body, and treatments focus on controlling its progression and improving the patient's quality of life. The drug is distributed through various channels, such as direct sales, pharmaceutical wholesalers, and online pharmacies. Its end users include hospitals, oncology clinics, and home healthcare providers.
The portrazza market research report is one of a series of new reports that provides portrazza market statistics, including the portrazza industry global market size, regional shares, competitors with the portrazza market share, detailed portrazza market segments, market trends, and opportunities, and any further data you may need to thrive in the portrazza industry. This portrazza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The portrazza market consists of sales of portrazza (necitumumab) injections, chemotherapy drugs, and supportive care drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Portrazza Market Characteristics4. Portrazza Market Trends and Strategies5. Portrazza Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Portrazza Pricing Analysis & Forecasts30. Global Portrazza Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Portrazza Market32. Recent Developments in the Portrazza Market
3. Portrazza Market Biologic Drug Characteristics
6. Global Portrazza Growth Analysis and Strategic Analysis Framework
8. Portrazza Market Segmentation
9. Global Portrazza Epidemiology of Clinical Indications
10. Portrazza Market Regional and Country Analysis
11. Asia-Pacific Portrazza Market
12. China Portrazza Market
13. India Portrazza Market
14. Japan Portrazza Market
15. Australia Portrazza Market
16. South Korea Portrazza Market
17. Western Europe Portrazza Market
18. UK Portrazza Market
19. Germany Portrazza Market
20. France Portrazza Market
21. Eastern Europe Portrazza Market
22. North America Portrazza Market
23. USA Portrazza Market
24. Canada Portrazza Market
25. South America Portrazza Market
26. Middle East Portrazza Market
27. Africa Portrazza Market
28. Portrazza Market Competitive Landscape and Company Profiles
29. Global Portrazza Market Pipeline Analysis
33. Portrazza Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Portrazza Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on portrazza market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for portrazza? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The portrazza market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Metastatic Squamous Non-Small Cell Lung Cancer; Locally Advanced Squamous Non-Small Cell Lung Cancer2) by Distribution Channel: Direct Sales; Pharmaceutical Wholesalers; Online Pharmacies
3) by End User: Hospitals; Oncology Clinics; Home Healthcare Providers
Key Companies Mentioned: Eli Lilly and Company
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Eli Lilly and Company
